Antidepressant dispensing trends in New Zealand between 2004 and 2007

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 12, 2009, Pages 1131-1140

  Exeter, Daniel ^a   Robinson, Elizabeth ^a   Wheeler, Amanda ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Antidepressant; Depression; Ethnicity; Prescribing

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADOLESCENT; ADULT; AGE SPECIFIC CARE; AGED; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; MALE; NEW ZEALAND; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; SEX FACTORS;

EID: 72749107261     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048670903279879     Document Type: Article

References (41)

1. Oakley Browne MA, Wells JE, Scott KM, McGee MA, for the New Zealand Mental Health Survey Research Team. Lifetime prevalence and projected lifetime risk of DSM-IV disorders in Te Rau Hinengaro: the New Zealand Mental Health Survey. Aust N Z J Psychiatry 2007; 40:865-874.
2. Wells JE, Browne MAO, Scott KM et al. Prevalence, interference with life and severity of 12 month DSM-IV disorders in Te Rau Hinengaro: the New Zealand Mental Health Survey. Aust N Z J Psychiatry 2006; 40:845-854.
3. Baxter J, Kokaua J, Wells JE, McGee MA, Browne MAO, for the New Zealand Mental Health Survey Research Team. Ethnic comparisons of the 12 month prevalence of mental disorders and treatment contact in Te Rau Hinengaro: the New Zealand Mental Health Survey. Aust N Z J Psychiatry 2006; 40:905-913. (Pubitemid 44309107)
4. Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343-396.
5. New Zealand Guidelines Group. Identification of common mental disorders and management of depression in primary care. Wellington: Ministry of Health, 2008.
6. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004; 38:389-407.
7. Pharmaceutical Management Agency. New Zealand pharmaceutical schedule. Wellington: Pharmaceutical Management Agency (PHARMAC), 2008.
8. Joyce PR, Mulder RT, Luty SE et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002; 36: 384-391.
9. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry 2007; 19:247-255.
10. Emslie GJ, Kennard BD, Mayes TL et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165:459-467.
11. Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-1037.
12. Hughes CW, Emslie GJ, Crismon ML et al. Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:667-686.
13. Roberts E, Norris P. Growth and change in the prescribing of anti-depressants in New Zealand: 1993-1997. N Z Med J 2001; 114:25-27.
14. Roberts E, Norris P. Regional variation in anti-depressant dispensings in New Zealand: 1993-1997. N Z Med J 2001; 114:27-30.
15. PHARMAC. Introduction to Pharmac. Wellington, NZ: PHARMAC, 2009.
16. Statistics New Zealand. The census of population and dwellings. Wellington, NZ: Statistics New Zealand, 2006.
17. Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors for major depression. Part 1. Evaluation of the clinical literature. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997.
18. Donoghue J, Tylee A, Wildgust H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ 1996; 313:861-862.
19. Hull SA, Aquino P, Cotter S. Explaining variation in antidepressant prescribing rates in east London: a cross sectional study. Fam Pract 2005; 22:37-42.
20. Hull SA, Cornwell J, Harvey C, Eldridge S, Bare PO. Prescribing rates for psychotropic medication amongst east London general practices: low rates where Asian populations are greatest. Fam Pract 2001; 18:167-173.
21. McManus P, Mant A, Mitchell PB, Montgomery WS, Marley J, Auland ME. Recent trends in the use of antidepressant drugs in Australia, 1990-1998. Med J Aust 2000; 173:458-461.
22. Arroll B, Goodyear-Smith F, Kerse N et al. The prevalence of depression among Maori patients in Auckland general practice. JPHC 2009; 1:26-29.
23. Raymond CB, Morgan SG, Caetano PA. Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatr Serv 2007; 58:79-84.
24. Rosholm JU, Andersen M, Gram LF. Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol 2001; 56:923-929.
25. Isacsson G, Boeìthius G, Henriksson S, Jones JK, Bergman U. Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database. J Affect Disord 1999; 53:15-22.
26. Percudani M, Barbui C, Fortino I, Petrovich L. Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord 2004; 83:169-175.
27. Arroll B, Goodyear-Smith F, Lloyd T. Depression in patients in an Auckland general practice. N Z Med J 2002; 115:176-179. (Pubitemid 36004449)
28. National Health Committee. Guidelines for the treatment and management of depression by primary healthcare professionals. Wellington, NZ: National Advisory Committee on Health and Disability, 1996.
29. Crampton P, Jatrana S, Lay-Yee R, Davis P. Exposure to primary medical care in New Zealand: number and duration of general practitioner visits. N Z Med J 2007; 120:U2582.
30. Jatrana S, Blakely T. Ethnic inequalities in mortality among the elderly in New Zealand. Aust NZ J Publ Health 2008; 32: 437-443.
31. Ajwani S, Blakely T, Robson B, Tobias M, Bonne M. Decades of disparity: ethnic mortality trends in New Zealand 1980-1999. Wellington, NZ: Ministry of Health and University of Otago, 2003.
32. Haynes R, Pearce J, Barnett R. Cancer survival in New Zealand: ethnic, social and geographical inequalities. Soc Sci Med 2008; 67:928-937.
33. Mantell CD, Craig ED, Stewart AW, Ekeroma AJ, Mitchell EA. Ethnicity and birth outcome: New Zealand trends 1980-2001: part 2. Pregnancy outcomes for Maori women. Aust N Z J Obstet Gynaecol 2004; 44:537-540.
34. Pearce N, Pomare E, Marshall S, Borman B. Mortality and socialclass in Maori and non-Maori New-Zealand men: changes between 1975-7 and 1985-7. N Z Med J 1993; 106:193-196.
35. Norris P, Calcott P, Laugesen M. The prescribing of new antidepressants in NZ. N Z Family Physician 1998; 25:45-49.
36. Joyce PR. Improvements in the recognition and treatment of depression and decreasing suicide rates. N Z Med J 2001; 114:535-536.
37. Mulder RT, Joyce PR, Frampton CMA, Luty SE. Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatr Scand 2008; 118:116-122.
38. Castelpietra G, Morsanutto A, Pascolo-Fabrici E, Isacsson G. Antidepressant use and suicide prevention: a prescription database study in the region Friuli Venezia Giulia, Italy. Acta Psychiatr Scand 2008; 118:382-388.
39. Gibbons RD, Brown CH, Hur K et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164: 1356-1363.
40. Wilson I, Duszynski K, Mant A. A 5-year follow-up of general practice patients experiencing depression. Family Practice 2003; 20:685-689.
41. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. Oslo: WHO, 2009.